Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- SBC Medical to Participate in Several Upcoming Investor Conferences in October 2026SBC Medical announces its participation in 3 upcoming investor conferences in Oct 2026, featuring presentations and 1on1 meetings with investors.
- Fresenius Medical Care Holdings, Inc.Fresenius Medical Care Refines China Commercial Strategy with a Focus on Long-Term Growth and Market LeadershipCompanies: Fresenius SE & Co. KGaARefinements support the Company's China go-to-market and commercial strategy in an important and growing market Strategy focuses on localized portfolio and innovation in China Portfolio decisions expected to result in related one-time costs in Q3 2026 treated as a special item BAD...
- Nutshell Therapeutics (Shanghai) Co., Ltd.Second NRF2 Degrader Enters Clinical Development: Nutshell Therapeutics' NTS231 Received FDA IND ClearanceNutshell Therapeutics (Shanghai) Co., Ltd. ("Nutshell Therapeutics"), an innovative biotech company focused on AI-driven allosteric drug discovery, announced FDA IND clearance for NTS231, a covalent allosteric molecular glue degrader of NRF2, to...
- Izotropic CorporationIzotropic Announces Non-Brokered Private PlacementIzotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing IzoView, a dedicated breast CT imaging system for the more accurate screening and diagnosis of breast cancers, announces the intention to complete a non-brokered private placement (the "Offering") with of 750,000 units of the Company with a strategic investor, (each a...
- Nutriband Appoints Decorated Navy SEAL and Veterans Health Advocate Robert J. O'Neill to Advisory BoardNutriband Appoints Decorated Navy SEAL and Veterans Health Advocate Robert J. O'Neill to Advisory Board
- neurocare and Wave Neuroscience partner to expand patient access to FDA-Cleared MeRT® therapy for PTSD on the Apollo TMS Therapy Systemneurocare and Wave Neuroscience collaborate to bring FDA-cleared MeRT® for PTSD to the Apollo TMS platform and provider network.
- Memorial Healthcare SystemMemorial Maintains Historic Low Tax RateThe South Broward Hospital District Board of Commissioners has unanimously approved maintaining its millage rate at 0.0805, the lowest in the district's recorded history. The 0.0805 rate was established in 2025 following 15 consecutive years...
- Global Medical Engineered Materials Market and Competition Outlook 2026-2032 | Demand Rises for Advanced Devices, Implants and Biocompatible Solutions"Medical Engineered Materials - A Global Market Overview" has been added to ResearchAndMarkets.com's offering.
- Amen Clinics, Inc.Dr. Daniel Amen Marks 20 Years on Public Television With New "BRAIN RESCUE" SpecialLive Southern California filming will give audiences practical strategies to protect memory, mood, brain health and their future — Twenty years after bringing brain health education to public television audiences, psychiatrist and...
- Avacta Group plc: The FOCUS-01 Clinical Trial Design and Preclinical Data Further Demonstrate the Potential of AVA6103 at AACR Conference on Pancreatic CancerAvacta Therapeutics (AIM: AVCT, the "Company", "Avacta"), a life sciences company developing innovative, targeted oncology drugs, today announces the presentation of the FOCUS-01 trial design and preclinical data highlighting the potential of AVA6103 (FAP-Exd) in pancreatic ductal adenocarcinoma (PDAC). FOCUS-01 is the Phase 1 trial of AVA6103, the Company's first Next-Generation pre|CISION® peptide-drug conjugate (PDC) and is being presented at the American Association for Cancer Research ("AACR") Conference on Pancreatic Cancer in San Diego, California, held between 25-28 September 2026.
- Car Accident Claim: Understanding Potential CompensationLearn how a car accident claim may address eligible losses, including vehicle damage, medical costs, lost income, and related expenses.
- CROSSJECT structure sa gouvernance pour la phase de déploiement industriel et commercialDIJON, FRANCE, 25 septembre 2026 – 07h30 (CEST) – CROSSJECT (ISIN : FR0011716265 ; Euronext Growth : ALCJ), la Specialty Pharma qui développe des solutions innovantes dédiées aux situations d’urgence, reposant sur sa technologie unique d’auto-injecteur sans aiguille ZENEO®, annonce que son Conseil de Surveillance, réuni le 24 septembre 2026, a nommé à l’unanimité Olivier LACOMBE, Didier MORIN et Lionel SELTZ membres du Directoire, leur nomination prend effet immédiatement et leur mandat expirera le 17 février 2029.